DENVER, Colo. (247marketnews.com) -- The market may be treating Capricor Therapeutics (NASDAQ:CAPR) as if the July 29 FDA advisory committee vote delivered a knockout blow, but it didn't. It delivered a major setback, but the actual regulatory story appears to be considerably more complicated and, with the Deramiocel BLA still under active FDA review and a PDUFA action date of August 22, the most important decision has yet to be made.
The advisory committee voted 3-9 against whether the available evidence constituted substantial evidence of effectiveness for Deramiocel in treating cardiomyopathy in Duchenne muscular dystrophy (DMD). But that question was narrower than the entire Deramiocel program. The committee was not asked to vote on the HOPE-3 primary endpoint or overall benefit-risk, and Capricor says discussion of upper-limb function was directionally supportive. The FDA's committee recommendation is advisory, not binding.
And there is a crucial piece of new evidence that arrived after the controversy intensified: the complete 106-patient, randomized, double-blind, placebo-controlled HOPE-3 Phase 3 dataset was published in The Lancet following independent peer review. Deramiocel achieved its primary endpoint on upper-limb function, with the company reporting a 54% slowing of upper-limb decline versus placebo and p=0.03.
Capricor’s CEO, Linda Marbán, is explicitly arguing that the advisory committee's vote should not be interpreted as a rejection of the broader clinical evidence, “We continue to believe there is a path to approval for Deramiocel.”
She also emphasized that HOPE-3 was specifically designed and powered around upper-limb function, while cardiac function was a key secondary endpoint.
There is another important wrinkle: Capricor disclosed that, during the Lancet peer-review process, it identified a statistical-model issue affecting the left-ventricular-ejection-fraction analysis. The company reverted to the prespecified statistical analysis plan. The LVEF result became p=0.09 rather than p=0.04, but Capricor says the HOPE-3 primary endpoint was unaffected, as was the prespecified cardiomyopathy subgroup result of p=0.02.
Meanwhile, Capricor administered nearly 1,300 Deramiocel infusions to more than 200 DMD patients, with some open-label-extension patients receiving treatment for more than five years. The company says the long-term safety profile remains consistent and well characterized.
The financial position also gives CAPR room to fight the regulatory battle, as Capricor ended June with approximately $237.9 million in cash, cash equivalents and marketable securities, which it says should fund operations for at least the next twelve months under its current plan.
That doesn't make the stock low-risk. The FDA could still reject the BLA, request additional evidence, or impose a more difficult path to approval. The July FDA bioresearch-monitoring inspection also produced a Form 483 with one observation, to which Capricor has responded. And the company's dispute with NS Pharma adds another layer of uncertainty around commercialization and economics.
Which is precisely why the next few days could be unusually important.
CAPR is no longer simply a Phase 3 biotech waiting to see whether its drug works. It has a completed BLA under active FDA review, peer-reviewed Phase 3 data, years of clinical experience, substantial cash, manufacturing infrastructure already being prepared for a potential launch and a regulator now forced to make its own determination after an advisory committee.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.